Table 1.
Clinicopathological and immunohistochemical factors in relation to SFRP2 immunoreactivity
| SFRP2 immunoreactivity | |||||
| Variable | na | IRS 0 – 4 (%) | IRS > 4 (%) | Rd | Pe |
| Total | 125 | 93 (74) | 32 (26) | ||
| Clinicopathological factors | |||||
| Age at diagnosis (median: 57 years; range 29 – 82 years) | |||||
| < 60 years | 69 | 49 (71) | 20 (29) | -0.103 | 0.255 |
| ≥ 60 years | 55 | 44 (80) | 11 (20) | ||
| Tumor sizeb | |||||
| pT1 | 42 | 29 (69) | 13 (31) | -0.110 | 0.226 |
| pT2 – 4 | 81 | 64 (79) | 17 (21) | ||
| Lymph node statusb | |||||
| pN0 | 62 | 41 (66) | 21 (34) | -0.194 | 0.033 |
| pN1 – 3 | 59 | 49 (83) | 10 (17) | ||
| Histological grade | |||||
| G1 – G2 | 67 | 49 (73) | 18 (27) | -0.047 | 0.606 |
| G3 | 57 | 44 (77) | 13 (23) | ||
| Histological type | |||||
| ductal | 98 | 73 (75) | 25 (26) | 0.024 | 0.796 |
| lobular | 9 | 9 (100) | 0 (0) | ||
| other | 14 | 9 (64) | 5 (36) | ||
| Immunohistochemistry | |||||
| Estrogen receptor status | |||||
| negative (IRSc 0 – 2) | 28 | 20 (71) | 8 (29) | -0.079 | 0.424 |
| positive (IRS 3 – 12) | 76 | 60 (79) | 16 (21) | ||
| Progesterone receptor status | |||||
| negative (IRSc 0 – 2) | 72 | 55 (76) | 17 (24) | 0.048 | 0.611 |
| positive (IRS 3 – 12) | 43 | 31 (72) | 12 (28) | ||
| Her2 | |||||
| negative (0, 1+) | 91 | 70 (77) | 21 (23) | 0.110 | 0.238 |
| positive (2+, 3+) | 26 | 17 (65) | 9 (35) | ||
| p53 | |||||
| negative (< 5%) | 70 | 53 (76) | 17 (24) | 0.033 | 0.724 |
| positive (≥ 5%) | 44 | 32 (73) | 12 (27) | ||
aOnly female patients with primary, unilateral, invasive breast cancer were included. bAccording to UICC: TNM Classification of Malignant Tumours [38]. cIRS = immunoreactivity score according to Remmele and Stegner [40]. dPearson's correlation coefficient. eFisher's exact test (two-sided). Significant P-values are marked in bold face. Percentages may not sum to 100 due to rounding.